Soros Fund Management LLC Decreases Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Soros Fund Management LLC lessened its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 700,000 shares of the company's stock after selling 50,000 shares during the quarter. Soros Fund Management LLC owned about 0.58% of Privia Health Group worth $13,685,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Quadrant Capital Group LLC increased its position in Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares during the period. Park Avenue Securities LLC grew its position in Privia Health Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 14,697 shares of the company's stock valued at $287,000 after buying an additional 532 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Privia Health Group by 8.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company's stock valued at $140,000 after buying an additional 533 shares during the period. First Horizon Advisors Inc. raised its position in Privia Health Group by 53.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after buying an additional 632 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Privia Health Group by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 10,673 shares of the company's stock worth $209,000 after acquiring an additional 678 shares during the period. Institutional investors and hedge funds own 94.48% of the company's stock.

Insider Buying and Selling at Privia Health Group

In related news, CEO Parth Mehrotra sold 15,100 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $352,283.00. Following the sale, the chief executive officer now directly owns 454,281 shares of the company's stock, valued at approximately $10,598,375.73. This trade represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Mountcastle sold 5,630 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the transaction, the chief financial officer now directly owns 179,676 shares of the company's stock, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,484 shares of company stock worth $799,163 in the last 90 days. 10.70% of the stock is owned by company insiders.

Privia Health Group Stock Up 1.8 %

Shares of NASDAQ:PRVA traded up $0.42 during midday trading on Friday, reaching $23.32. The company's stock had a trading volume of 369,530 shares, compared to its average volume of 770,831. The business has a 50 day moving average price of $23.50 and a 200 day moving average price of $22.10. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $26.04. The firm has a market cap of $2.83 billion, a price-to-earnings ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Robert W. Baird upped their target price on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a report on Tuesday, April 15th. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 price target on shares of Privia Health Group in a research note on Monday, April 28th. Truist Financial boosted their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group raised their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Privia Health Group has an average rating of "Buy" and a consensus price target of $27.38.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.